SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in the SVB Securities Global Biopharma Conference and Cowen’s 43rd Annual Health Care Conference. Details of participation are as follows:
SVB Securities Global Biopharma Conference
Company Presentation
Date: February 16, 2023
Time: 1:00 PM ET – 1:30 PM ET
Cowen’s 43rd Annual Health Care Conference
Genetic Medicines Panel
Date: March 6, 2023
Time: 10:30 AM ET – 11:30 AM ET
A webcast of both events will be available by visiting the Investors section of Tenaya’s website.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic cardiovascular disorders, as well as for more prevalent heart conditions, through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.
Contacts
Investors
Michelle Corral
Vice President, Investor Relations and Corporate Communications
Tenaya Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Wendy Ryan
Ten Bridge Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.15 |
| Daily Change: | 0.20 21.45 |
| Daily Volume: | 8,572,567 |
| Market Cap: | US$187.070M |
August 06, 2025 May 07, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
